Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 8/20 | 0.66 |
| ▸ | MAPT | P10636 | 4/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 3/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | BAX | Q07812 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | RAD52 | P43351 | 1/20 | 0.49 |
| ▸ | PER2 | O15055 | 1/20 | 0.45 |
| ▸ | CRY1 | Q16526 | 1/20 | 0.45 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14689590 | 0.88 | DNM1 (0.61) | DNM1MAPTSMN1; SMN2HTTNPSR1 | |
| SCHEMBL14690001 | 0.85 | DNM1 (0.58) | DNM1MAPTSMN1; SMN2HTTNPSR1 | |
| SCHEMBL14689687 | 0.85 | TSPO (0.52) | DNM1MAPTSMN1; SMN2HTTNPSR1 | |
| SCHEMBL14701124 | 0.85 | DNM1 (0.57) | DNM1MAPTSMN1; SMN2HTTNPSR1 | |
| SCHEMBL14689388 | 0.84 | DNM1 (0.57) | DNM1MAPTSMN1; SMN2HTTNPSR1 | |
| SCHEMBL15486884 | 0.84 | DNM1 (0.70) | DNM1MAPTSMN1; SMN2HTTNPSR1 | |
| SCHEMBL410834 | 0.82 | DNM1 (0.73) | DNM1MAPTSMN1; SMN2HTTNPSR1 | |
| SCHEMBL14701123 | 0.81 | DNM1 (0.54) | DNM1MAPTSMN1; SMN2HTTNPSR1 | |
| SCHEMBL16099375 | 0.81 | DNM1 (0.67) | DNM1MAPTSMN1; SMN2HTTNPSR1 | |
| SCHEMBL410147 | 0.80 | DNM1 (1.00) | DNM1MAPTSMN1; SMN2HTTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180318255-A1 | Pro-Neurogenic Compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2018-11-08 | — | — | US | claimed |
| EP-2925129-A1 | PRO-NEUROGENIC COMPOUNDS | Board of Regents of the University of Texas System (US) | 2015-10-07 | — | — | EP | claimed |
| WO-2014031125-A1 | PRO-NEUROGENIC COMPOUNDS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-02-27 | — | — | WO | claimed |
| US-20130040977-A1 | Pro-Neurogenic Compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2013-02-14 | — | — | US | claimed |
| US-20190218203-A1 | Neuroprotective Compounds and Use Thereof | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2019-07-18 | — | — | US | disclosed |
| US-10183011-B2 | Anti-depression compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-01-22 | — | — | US | disclosed |
| US-20180318255-A1 | Pro-Neurogenic Compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2018-11-08 | — | — | US | disclosed |
| US-9962368-B2 | Pro-neurogenic compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-05-08 | — | — | US | disclosed |
| US-9902713-B2 | Neuroprotective compounds and use thereof | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-02-27 | — | — | US | disclosed |
| US-20170307592-A1 | Neuroprotective Chemicals and Methods for Identifying and Using Same | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2017-10-26 | — | — | US | disclosed |
| US-20170157092-A1 | Anti-depression Compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2017-06-08 | — | — | US | disclosed |
| US-9645139-B2 | Neuroprotective chemicals and methods for identifying and using same | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-05-09 | — | — | US | disclosed |
| WO-2015070237-A1 | NEUROPROTECTIVE CHEMICALS AND METHODS FOR IDENTIFYING AND USING SAME | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-05-14 | — | — | WO | disclosed |
| US-20140343018-A1 | Anti-depression Compounds | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2014-11-20 | — | — | US | disclosed |
| US-8877797-B2 | Methods for treating Parkinson's disease using pro-neurogenic compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-11-04 | — | — | US | disclosed |
| US-8735440-B2 | Methods for treating amyotrophic lateral sclerosis using pro-neurogenic compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-05-27 | — | — | US | disclosed |
| WO-2014031125-A1 | PRO-NEUROGENIC COMPOUNDS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-02-27 | — | — | WO | disclosed |
| US-20130190273-A1 | Methods for Treating Amyotrophic Lateral Sclerosis Using Pro-Neurogenic Compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130184271-A1 | Methods for Treating Parkinson's Disease Using Pro-Neurogenic Compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-07-18 | — | — | US | disclosed |
| US-20130040977-A1 | Pro-Neurogenic Compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2013-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218203-A1 | Neuroprotective Compounds and Use Thereof | NLN, GAP43, BDNF | DNM1 1332/4885MAPT 42/4885SMN1; SMN2 4/4885 |
| US-20130184271-A1 | Methods for Treating Parkinson's Disease Using Pro-Neurogenic Compounds | BDNF, GAP43, NES | DNM1 677/4885MAPT 141/4885SMN1; SMN2 60/4885 |
| US-20170307592-A1 | Neuroprotective Chemicals and Methods for Identifying and Using Same | NLN, AIFM1, AIFM2 | DNM1 1465/4885MAPT 236/4885SMN1; SMN2 41/4885 |
| US-20130190273-A1 | Methods for Treating Amyotrophic Lateral Sclerosis Using Pro-Neurogenic Compounds | BDNF, GAP43, DCX | DNM1 610/4885MAPT 122/4885SMN1; SMN2 19/4885 |
| US-20180318255-A1 | Pro-Neurogenic Compounds | BDNF, GAP43, DCX | DNM1 897/4885MAPT 136/4885SMN1; SMN2 50/4885 |
| US-10183011-B2 | Anti-depression compounds | BDNF, DCX, GAP43 | DNM1 638/4885MAPT 142/4885SMN1; SMN2 63/4885 |
| US-20140343018-A1 | Anti-depression Compounds | BDNF, DCX, GAP43 | DNM1 638/4885MAPT 142/4885SMN1; SMN2 63/4885 |
| US-20130040977-A1 | Pro-Neurogenic Compounds | BDNF, GAP43, DCX | DNM1 897/4885MAPT 136/4885SMN1; SMN2 50/4885 |
| US-20170157092-A1 | Anti-depression Compounds | BDNF, DCX, GAP43 | DNM1 638/4885MAPT 142/4885SMN1; SMN2 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.